Concentrations of 6-thioguanine nucleotide (6-TGN) less than 230 pmol/8 x 108
RBC may indicate a reduced response to therapy; 6-TGN concentrations greater than 400 pmol/8 x 108
RBC may indicate a higher risk for leukopenia. Concentrations of 6-methyl mercaptopurine nucleotide (6-MMPN) greater than 5700 pmol/8 x 108
RBC may indicate a higher risk for hepatotoxicity.
Compliance Statement B
: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.